Analyst upgrades typically lead to a positive short-term reaction in a stock's price as they suggest a better-than-expected future performance. The upgrade from 'Hold' to 'Buy' and the significant price target of $15 by Jefferies for Vistagen Therapeutics is likely to be viewed favorably by investors, potentially driving up the stock price in the short term.